Literature DB >> 2103328

Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1.

R Peter1, R Böcker, P H Beaune, M Iwasaki, F P Guengerich, C S Yang.   

Abstract

Human cytochrome P-450IIE1 has been implicated in the oxidation of a number of substrates, including protoxins and -carcinogens. To date, no drugs have been identified that are exclusive substrates for the protein and are applicable for use as noninvasive probes of the in vivo function of the enzyme in humans. Chlorzoxazone was found to be oxidized only to 6-hydroxychlorzoxazone in human liver microsomes. Results of steady-state kinetics are consistent with the view that only a single enzyme catalyzes the reaction. The microsomal reaction was strongly inhibited by rabbit anti-P-450IIE1 and, in a competitive manner, by known P-450IIE1 substrates. Rates of chlorzoxazone 6-hydroxylation in different human liver microsomal preparations were well correlated with levels of immunochemically measured P-450IIE1 and rates of (CH3)2NNO oxidation. Chlorzoxazone 6-hydroxylation was also found to be catalyzed by purified human liver P-450IIE1. These results provide strong evidence that P-450IIE1 is the primary catalyst of chlorzoxazone 6-hydroxylation in human liver. Rates of chlorzoxazone 6-hydroxylation vary considerably among human liver samples, and chlorzoxazone 6-hydroxylation may have potential use as a noninvasive probe in estimating the in vivo expression of human P-450IIE1 and its significance as a risk factor in the toxicity and carcinogenicity of a number of solvents, nitrosamines, and drugs.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2103328     DOI: 10.1021/tx00018a012

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  55 in total

Review 1.  Dietary effects on drug metabolism and transport.

Authors:  Robert Z Harris; Graham R Jang; Shirley Tsunoda
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Comparison of chlorzoxazone one-sample methods to estimate CYP2E1 activity in humans.

Authors:  Iza Kramer; Kim Dalhoff; Jens O Clemmesen; Steffen Loft; Henrik E Poulsen
Journal:  Eur J Clin Pharmacol       Date:  2003-11-11       Impact factor: 2.953

3.  Chlorzoxazone metabolism is increased in fasted Sprague-Dawley rats.

Authors:  Jie Wan; Lena Ernstgård; Byoung J Song; Susan E Shoaf
Journal:  J Pharm Pharmacol       Date:  2006-01       Impact factor: 3.765

4.  Functional characterisation of an engineered multidomain human P450 2E1 by molecular Lego.

Authors:  Michael Fairhead; Silva Giannini; Elizabeth M J Gillam; Gianfranco Gilardi
Journal:  J Biol Inorg Chem       Date:  2005-11-09       Impact factor: 3.358

5.  A human PBPK model for ethanol describing inhibition of gastric motility.

Authors:  George D Loizou; Martin Spendiff
Journal:  J Mol Histol       Date:  2004-09       Impact factor: 2.611

Review 6.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

7.  The effects of nitrogen-heme-iron coordination on substrate affinities for cytochrome P450 2E1.

Authors:  Jeffrey P Jones; Carolyn A Joswig-Jones; Michelle Hebner; Yuzhuo Chu; Dennis R Koop
Journal:  Chem Biol Interact       Date:  2011-05-10       Impact factor: 5.192

8.  Diabetes mellitus increases the in vivo activity of cytochrome P450 2E1 in humans.

Authors:  Zaiqi Wang; Stephen D Hall; Juan F Maya; Lang Li; Ali Asghar; J C Gorski
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

9.  Structures of human cytochrome P-450 2E1. Insights into the binding of inhibitors and both small molecular weight and fatty acid substrates.

Authors:  Patrick R Porubsky; Kathleen M Meneely; Emily E Scott
Journal:  J Biol Chem       Date:  2008-09-24       Impact factor: 5.157

10.  A convenient five-drug cocktail for the assessment of major drug metabolizing enzymes: a pilot study.

Authors:  Ashish Sharma; Sylvie Pilote; Pierre M Bélanger; Marie Arsenault; Bettina A Hamelin
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.